Essential Thrombocythemia

  • Jaime AaronsonEmail author


Essential thrombocythemia (ET) is an acquired, Philadelphia chromosome-negative myeloproliferative neoplasm (MPN) that is characterized by a sustained elevation in platelet count (greater than 450 G/l on two occasions). Parturients with ET are at risk of hemorrhagic and, more commonly, thromboembolic events. If anticoagulated, the timing of neuraxial block will need to occur within a safe window. Early delivery planning with a multidisciplinary care team is, therefore, prudent and may prevent the need for an alternative to neuraxial analgesia/anesthesia.


Essential thrombocythemia Anticoagulation Neuraxial analgesia/anesthesia 


  1. 1.
    Valera M-C, Parant O, Vayssiere C, Arnal J-F, Payrastre B. Essential thrombocythemia and pregnancy. Eur J Obstet Gynecol Reprod Biol. 2011;158(2):141–7.CrossRefGoogle Scholar
  2. 2.
    Chow EY, Haley LP, Vickars LM. Essential thrombocythemia in pregnancy: platelet count and pregnancy outcome. Am J Hematol. 1992;41(4):249–51.CrossRefGoogle Scholar
  3. 3.
    Villani M, Colaizzo D, Tiscia GL, Chinni E, Bodenizza C, Cascavilla N, et al. Postpartum haemorrhage in a woman with essential thrombocythemia carrying calreticulin mutation. Blood Coagul Fibrinolysis. 2016;27(6):727–8.CrossRefGoogle Scholar
  4. 4.
    Randi ML, Bertozzi I, Rumi E, Elena C, Finazzi G, Vianelli N, et al. Pregnancy complications predict thrombotic events in young women with essential thrombocythemia. Am J Hematol. 2014;89(3):306–9.CrossRefGoogle Scholar
  5. 5.
    Harrison C. Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. Br J Haematol. 2005;129(3):293–306.CrossRefGoogle Scholar
  6. 6.
    Onisai M, Voican I, Ciorascu M, Popov V, Bumbea H, Gaman M, et al. Early severe preeclampsia with marked platelet dysfunction in association with essential thrombocytemia. Blood Coagul Fibrinolysis. 2015;26(7):830–7.CrossRefGoogle Scholar
  7. 7.
    Alimam S, Bewley S, Chappell LC, Knight M, Seed P, Gray G, et al. Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study. Br J Haematol. 2016;175(1):31–6.CrossRefGoogle Scholar
  8. 8.
    Griesshammer M, Struve S, Barbui T. Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy. Blood Rev. 2008;22:235–45.CrossRefGoogle Scholar
  9. 9.
    Finazzi G. How to manage essential thrombocythemia. Leukemia. 2011;26:875–82.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of AnesthesiologyNew York Presbyterian Weill Cornell MedicineNew YorkUSA

Personalised recommendations